Agios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.63), $0.03 worse than the analyst estimate of ($1.60). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $20.08 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.